Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Medicare Part D
100%
Out-of-pocket
100%
Coinsurance
100%
Rebates
100%
Drug Competition
100%
Drug Rebates
100%
List Price
66%
Net Price
50%
Prescription Drugs
33%
Out-of-pocket Expenditure
33%
Payers
33%
Point of Sale
33%
Pharmaceutical Competition
33%
Drug List
33%
Exposure Level
16%
Retrospective Cohort Study
16%
Disease Areas
16%
Retail Price
16%
Coverage Gap
16%
Cost Sharing
16%
Therapeutic Class
16%
Generic Equivalent
16%
National Drug Code
16%
Degree of Competition
16%
Public Listed Companies
16%
Generic Competition
16%
Price Markup
16%
Catastrophic Coverage
16%
Medicine and Dentistry
Medicare
100%
Prescription Drug
100%
Diseases
50%
Retrospective Cohort Study
50%
4 Chloro 3',6' Dimethyl 2,2' Iminodibenzoic Acid
50%
Cost Sharing
50%
Pharmacology, Toxicology and Pharmaceutical Science
Prescription Drug
100%
Diseases
50%
Cohort Study
50%
4 Chloro 3',6' Dimethyl 2,2' Iminodibenzoic Acid
50%
Economics, Econometrics and Finance
United States of America
100%
Publicly Traded Company
100%
Social Sciences
Sales
100%
Diseases
33%
United States of America
33%
Cost Sharing
33%